ID

16297

Beschreibung

Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00266110

Link

https://clinicaltrials.gov/show/NCT00266110

Stichworte

Versionen (1)
  1. 10.07.16 10.07.16 -
Hochgeladen am

10. Juli 2016

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Breast Cancer NCT00266110

Englisch

Eligibility Breast Cancer NCT00266110

1 Formulare  
Criteria
Beschreibung

Criteria

4.1 inclusion criteria 4.1.1 histologically proven metastatic breast cancer with measurable or evaluable disease per investigator discretion.
Beschreibung

metastatic breast cancer

Datentyp

boolean

Alias
UMLS CUI [1]
C0278488
4.1.2 patients must be 18 years of age or older. women of child bearing potential must be practicing barrier or oral contraception for the duration of the study, or documented as surgically sterile or one year post-menopausal.
Beschreibung

Age, contraception

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0700589
4.1.3 ecog performance status 0-2 (see appendix a).
Beschreibung

ecog performance status

Datentyp

boolean

Alias
UMLS CUI [1]
C1520224
4.1.5 cardiac function by muga with an ef > 45% or an echocardiogram that shows normal lv function.
Beschreibung

cardiac function

Datentyp

boolean

Alias
UMLS CUI [1]
C0232164
4.1.6 serum creatinine < 2.0 mg/dl. 4.1.7 hepatic transaminases (alanine aminotransferase (alt) and aspartate aminotransferase (ast)) ≤3.0 times the upper limit of normal if no liver metastases or ≤5 times the upper limit of normal if liver metastases are present.
Beschreibung

Liver function

Datentyp

boolean

Alias
UMLS CUI [1]
C0232741
UMLS CUI [2]
C0600061
UMLS CUI [3]
C0002594
4.1.8 bilirubin no more than 2x normal.
Beschreibung

bilirubin

Datentyp

boolean

Alias
UMLS CUI [1]
C1278039
4.1.9 seronegative for hiv.
Beschreibung

hiv

Datentyp

boolean

Alias
UMLS CUI [1]
C0019682
4.1.10 negative for hepatitis b surface antigen.
Beschreibung

hepatitis b surface antigen

Datentyp

boolean

Alias
UMLS CUI [1]
C0019168
4.1.11 signed and dated informed consent.
Beschreibung

informed consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
4.1.12 hla a0201+ by dna genotyping.
Beschreibung

HLA genotype

Datentyp

boolean

Alias
UMLS CUI [1]
C0019721
4.1.13 absolute neutrophil count greater than 1,500/mm3. platelet count greater 100,000/mm3 and hemoglobin greater than or equal to 10
Beschreibung

absolute neutrophil count, platelet count, hemoglobin

Datentyp

boolean

Alias
UMLS CUI [1]
C0200633
UMLS CUI [2]
C1287267
UMLS CUI [3]
C0019046
4.1.14. 3+ expression of her-2/neu from original pathology (diagnostic) tumor sample by ihc or 2+ expression by ihc with gene amplification by fish.
Beschreibung

her-2/neu

Datentyp

boolean

Alias
UMLS CUI [1]
C0242957
4.1.15. patients will be eligible even if they have failed treatment for metastatic breast cancer with trastuzumab and a chemotherapy agent other than vinorelbine or if they have progressed within 12 months of receiving adjuvant chemotherapy using trastuzumab and a taxane.
Beschreibung

treatment failure or progress

Datentyp

boolean

Alias
UMLS CUI [1]
C0162643
UMLS CUI [2]
C0178874
4.2 exclusion criteria
Beschreibung

Exclusion criteria

Datentyp

boolean

Alias
UMLS CUI [1]
C0680251
4.2.1 patients with any serious medical, cardiac, or psychiatric condition which, in the opinion of the investigator, would make the patient unsuitable for study participation or would impede probable compliance with the protocol.
Beschreibung

Comorbidity

Datentyp

boolean

Alias
UMLS CUI [1]
C0009488
UMLS CUI [2]
C0018799
UMLS CUI [3]
C0004936
4.2.2 patients with central nervous system metastases must have stable disease for at least 3 months prior to study entry.
Beschreibung

CNS metastases, stable disease

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0279130
UMLS CUI [1,2]
C0677946
4.2.3 patient is currently taking steroid medications. systemic steroid treatment is not allowed.
Beschreibung

Systemic steroid treatment

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0149783
UMLS CUI [1,2]
C0205373
4.2.4 patients that have failed prior therapy with vinorelbine + trastuzumab will not be eligible for therapy.
Beschreibung

Treatment failure of vinorelbine + trastuzumab

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0162643
UMLS CUI [1,2]
C0935819
4.2.5 patient has received hormonal or cytotoxic chemotherapy within 14 days of apheresis and within 28-30 days prior to study treatment.
Beschreibung

ID.19

Datentyp

boolean

Alias
UMLS CUI [1]
C0279025
UMLS CUI [2]
C0677881
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Breast Cancer NCT00266110

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
metastatic breast cancer
Item
4.1 inclusion criteria 4.1.1 histologically proven metastatic breast cancer with measurable or evaluable disease per investigator discretion.
boolean
C0278488 (UMLS CUI [1])
Age, contraception
Item
4.1.2 patients must be 18 years of age or older. women of child bearing potential must be practicing barrier or oral contraception for the duration of the study, or documented as surgically sterile or one year post-menopausal.
boolean
C0001779 (UMLS CUI [1])
C0700589 (UMLS CUI [2])
ecog performance status
Item
4.1.3 ecog performance status 0-2 (see appendix a).
boolean
C1520224 (UMLS CUI [1])
cardiac function
Item
4.1.5 cardiac function by muga with an ef > 45% or an echocardiogram that shows normal lv function.
boolean
C0232164 (UMLS CUI [1])
Liver function
Item
4.1.6 serum creatinine < 2.0 mg/dl. 4.1.7 hepatic transaminases (alanine aminotransferase (alt) and aspartate aminotransferase (ast)) ≤3.0 times the upper limit of normal if no liver metastases or ≤5 times the upper limit of normal if liver metastases are present.
boolean
C0232741 (UMLS CUI [1])
C0600061 (UMLS CUI [2])
C0002594 (UMLS CUI [3])
bilirubin
Item
4.1.8 bilirubin no more than 2x normal.
boolean
C1278039 (UMLS CUI [1])
hiv
Item
4.1.9 seronegative for hiv.
boolean
C0019682 (UMLS CUI [1])
hepatitis b surface antigen
Item
4.1.10 negative for hepatitis b surface antigen.
boolean
C0019168 (UMLS CUI [1])
informed consent
Item
4.1.11 signed and dated informed consent.
boolean
C0021430 (UMLS CUI [1])
HLA genotype
Item
4.1.12 hla a0201+ by dna genotyping.
boolean
C0019721 (UMLS CUI [1])
absolute neutrophil count, platelet count, hemoglobin
Item
4.1.13 absolute neutrophil count greater than 1,500/mm3. platelet count greater 100,000/mm3 and hemoglobin greater than or equal to 10
boolean
C0200633 (UMLS CUI [1])
C1287267 (UMLS CUI [2])
C0019046 (UMLS CUI [3])
her-2/neu
Item
4.1.14. 3+ expression of her-2/neu from original pathology (diagnostic) tumor sample by ihc or 2+ expression by ihc with gene amplification by fish.
boolean
C0242957 (UMLS CUI [1])
treatment failure or progress
Item
4.1.15. patients will be eligible even if they have failed treatment for metastatic breast cancer with trastuzumab and a chemotherapy agent other than vinorelbine or if they have progressed within 12 months of receiving adjuvant chemotherapy using trastuzumab and a taxane.
boolean
C0162643 (UMLS CUI [1])
C0178874 (UMLS CUI [2])
Exclusion criteria
Item
4.2 exclusion criteria
boolean
C0680251 (UMLS CUI [1])
Comorbidity
Item
4.2.1 patients with any serious medical, cardiac, or psychiatric condition which, in the opinion of the investigator, would make the patient unsuitable for study participation or would impede probable compliance with the protocol.
boolean
C0009488 (UMLS CUI [1])
C0018799 (UMLS CUI [2])
C0004936 (UMLS CUI [3])
CNS metastases, stable disease
Item
4.2.2 patients with central nervous system metastases must have stable disease for at least 3 months prior to study entry.
boolean
C0279130 (UMLS CUI [1,1])
C0677946 (UMLS CUI [1,2])
Systemic steroid treatment
Item
4.2.3 patient is currently taking steroid medications. systemic steroid treatment is not allowed.
boolean
C0149783 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
Treatment failure of vinorelbine + trastuzumab
Item
4.2.4 patients that have failed prior therapy with vinorelbine + trastuzumab will not be eligible for therapy.
boolean
C0162643 (UMLS CUI [1,1])
C0935819 (UMLS CUI [1,2])
ID.19
Item
4.2.5 patient has received hormonal or cytotoxic chemotherapy within 14 days of apheresis and within 28-30 days prior to study treatment.
boolean
C0279025 (UMLS CUI [1])
C0677881 (UMLS CUI [2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video